Collaboration Revenue - Related Party was Spero Therapeutics’s largest product and service line in fiscal 2025, bringing in $47.03M of $47.13M (100%).
| Product and Service | FY 2017 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Collaboration Revenue - Related Party | — | $95.80M | — | $47.03M | |
| Research & Development Services Related To Upcoming Milestones | $19.00M | — | — | — | |
| Collaboration Revenue | — | $933.00K | $371.00K | — | |
| Grant | — | — | — | — | |
| Spr206 | — | — | — | $100.00K | |
| Total | $19.00M | $96.74M | $371.00K | $47.13M |
Spero Therapeutics brought in $47.13M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Spero Therapeutics regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $371.00K. Collaboration Revenue - Related Party was the largest at $47.03M (99.8%), ahead of Spr206 at $100.00K (0.2%).
Spero Therapeutics began breaking out Collaboration Revenue - Related Party in fiscal 2023 and Spr206 in fiscal 2025. Spero Therapeutics stopped reporting Research & Development Services Related To Upcoming Milestones ($19.00M in fiscal 2022) and Collaboration Revenue ($371.00K in fiscal 2024) as separate lines.
Carb-X was Spero Therapeutics’s largest revenue line in fiscal 2017, bringing in $900.00K of $2.00M (45%).
| Research And Development Arrangement Contract To Perform For Others By Type | FY 2017 | FY 2017 |
|---|---|---|
| Carb-X | — | $900.00K |
| U.S. Department Of Defense | — | $700.00K |
| Niaid | $100.00K | $400.00K |
| Total | $100.00K | $2.00M |
Spero Therapeutics brought in $2.00M from its three revenue lines in fiscal 2017, the year ended December 31, 2017. Spero Therapeutics regrouped these revenue lines after fiscal 2017, so the total does not compare directly with that year's $100.00K. Carb-X was the largest at $900.00K (45.0%), ahead of U.S. Department Of Defense at $700.00K (35.0%) and Niaid at $400.00K (20.0%).
Spero Therapeutics (SPRO) reports its revenue by product and service and by research and development arrangement contract to perform for others by type. In fiscal 2025, Collaboration Revenue - Related Party was its largest product and service line, bringing in $47.03M (99.8% of the total), followed by Spr206 at $100.00K (0.2%).
Collaboration Revenue - Related Party was Spero Therapeutics' largest product and service line in fiscal 2025, bringing in $47.03M, or 99.8% of the $47.13M total across its two product and service lines.
Carb-X was Spero Therapeutics' largest revenue line in fiscal 2017, bringing in $900.00K, or 45.0% of the $2.00M total across its three revenue lines.
Every figure comes from Spero Therapeutics' annual financial filings, as reported. Each line keeps the name Spero Therapeutics gives it, and years follow its fiscal calendar.
Spero Therapeutics' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.